SK bioscience Co.,Ltd. 302440

SK bioscience announced that it has submitted a Clinical Trial Application (CTA) to the South African Health Products Regulatory Authority (SAHPRA) for a global pediatric Phase 1b clinical trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate licensed from the Gates Medical Research Institute (Gates MRI), a nonprofit medical research organization affiliated with the Gates Foundation.

SK bioscience announced that it will lead the Research Optimization & Trial Outcome Recommender (ROTOR) project, an AI-powered evidence synthesis and clinical development decision-support platform initiative funded by the Gates Foundation, establishing a global collaboration framework. The project is expected to involve technical collaboration with global health nonprofit PATH, and global technology consulting firm Slalom.

SK bioscience announced that it has been designated as a supplier of influenza vaccines for UNICEF's 2026 immunization programs and has begun shipments for countries in the Southern Hemisphere. Beginning in September, the company will also commence supplies for countries in the Northern Hemisphere, with approximately 640,000 doses scheduled for delivery throughout the year in accordance with each country's vaccination calendar.

SK bioscience is accelerating late-stage development of its innovative pneumococcal vaccine candidate targeting the global market, backed by government-supported financing.

Under the agreement, VECOL will act as the primary implementing partner while SK bioscience contributes technology transfer and manufacturing support.

SK bioscience announced that it has signed an agreement with Colombia's state-owned pharmaceutical company VECOL for vaccine technology transfer and local manufacturing cooperation as part of Colombia's national vaccine localization initiative.

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025.